Myelodysplastic Syndrome (MDS) Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center
|10-064-B||Molecular characterization of hematopoietic malignancies
|IRB14-0702||A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)
|12-0153||A phase 1b study to evaluate the safety and preliminary efficacy of PF-04449913, an oral hedgehog inhibitor, in combination with intensive chemotherapy, low dose ara-C or decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
|16840A||E2905: Randomized Phase III Trial
Comparing the Frequency of Major Erythroid
Response (MER) to Treatment with
Lenalidomide (Revlimid) Alone and in
Combination with Epoetin Alfa (Procrit) in
Subjects with Low- or
Intermediate-1 Risk MDS and Symptomatic
|16139B||A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes.
|IRB14-0331||A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
|09-130-B||A University of Chicago Leukemia Registry Protocol.
To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team